VAYHIT3 Trial of Ianalumab
Phase II VAYHIT3 Interim Results: Ianalumab in Previously Treated Primary Immune Thrombocytopenia 

Released: December 11, 2024

Expiration: December 10, 2025

Activity

Progress
1
Course Completed